320 related articles for article (PubMed ID: 18271931)
1. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment.
Sato S; Futakuchi M; Ogawa K; Asamoto M; Nakao K; Asai K; Shirai T
Cancer Sci; 2008 Feb; 99(2):316-23. PubMed ID: 18271931
[TBL] [Abstract][Full Text] [Related]
2. Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor β (TGFβ) signaling.
Karlsson T; Sundar R; Widmark A; Landström M; Persson E
Prostate; 2018 May; 78(6):446-456. PubMed ID: 29383751
[TBL] [Abstract][Full Text] [Related]
3. An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.
Thiolloy S; Edwards JR; Fingleton B; Rifkin DB; Matrisian LM; Lynch CC
PLoS One; 2012; 7(1):e29862. PubMed ID: 22238668
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.
Futakuchi M; Nannuru KC; Varney ML; Sadanandam A; Nakao K; Asai K; Shirai T; Sato SY; Singh RK
Cancer Sci; 2009 Jan; 100(1):71-81. PubMed ID: 19038005
[TBL] [Abstract][Full Text] [Related]
6. Conditional knockout of PDK1 in osteoclasts suppressed osteoclastogenesis and ameliorated prostate cancer-induced osteolysis in murine model.
Zhang Y; Nong H; Bai Y; Zhou Q; Zhang Q; Liu M; Liu P; Zeng G; Zong S
Eur J Med Res; 2023 Oct; 28(1):433. PubMed ID: 37828580
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Factor-Kappa B Regulation of Osteoclastogenesis and Osteoblastogenesis.
Boyce BF; Li J; Yao Z; Xing L
Endocrinol Metab (Seoul); 2023 Oct; 38(5):504-521. PubMed ID: 37749800
[TBL] [Abstract][Full Text] [Related]
8. A Role for TGFβ Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression.
Cheng JN; Frye JB; Whitman SA; Kunihiro AG; Pandey R; Funk JL
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923316
[TBL] [Abstract][Full Text] [Related]
9. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.
Sadanandam A; Futakuchi M; Lyssiotis CA; Gibb WJ; Singh RK
BMC Cancer; 2011 Jul; 11():304. PubMed ID: 21774828
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling.
Verona EV; Elkahloun AG; Yang J; Bandyopadhyay A; Yeh IT; Sun LZ
Cancer Res; 2007 Jun; 67(12):5737-46. PubMed ID: 17575140
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
Chirgwin JM; Guise TA
Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
[TBL] [Abstract][Full Text] [Related]
13. Bone Morphogenetic Protein-2 Promotes Osteoclasts-mediated Osteolysis via Smad1 and p65 Signaling Pathways.
Miao X; Yuan J; Wu J; Zheng J; Zheng W; Wang F; Wang C; Li X; Liu S; Shi Z; Li J
Spine (Phila Pa 1976); 2021 Feb; 46(4):E234-E242. PubMed ID: 33156278
[TBL] [Abstract][Full Text] [Related]
14. The downregulation of IGFBP3 by TGF-β signaling in oral cancer contributes to the osteoclast differentiation.
Park J; Jung MJ; Chung WY
Biochem Biophys Res Commun; 2021 Jan; 534():381-386. PubMed ID: 33256984
[TBL] [Abstract][Full Text] [Related]
15. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis.
Thiolloy S; Halpern J; Holt GE; Schwartz HS; Mundy GR; Matrisian LM; Lynch CC
Cancer Res; 2009 Aug; 69(16):6747-55. PubMed ID: 19679556
[TBL] [Abstract][Full Text] [Related]
16. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
[TBL] [Abstract][Full Text] [Related]
17. Artemisinin inhibits breast cancer-induced osteolysis by inhibiting osteoclast formation and breast cancer cell proliferation.
Li J; Feng W; Lu H; Wei Y; Ma S; Wei L; Liu Q; Zhao J; Wei Q; Yao J
J Cell Physiol; 2019 Aug; 234(8):12663-12675. PubMed ID: 30536376
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
19. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
20. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
